NCT06109870 is a NA clinical trial of PRECEDE-PROCEED in HPV, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT06109870?

NCT06109870 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT06109870?

Interventions in NCT06109870: PRECEDE-PROCEED.

Is NCT06109870 still recruiting?

NCT06109870 is currently recruiting now. Last updated 4 March 2026.

Last reviewed 2026-03-04 · How we verify

NCT06109870

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening

Recruiting now NA Last updated 4 March 2026

What this trial tests

NA trial testing PRECEDE-PROCEED in HPV in 920 participants. Currently enrolling.

Timeline

30 October 2023

Primary endpoint
31 August 2028

31 August 2030

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	920
Start date	30 October 2023
Primary completion	31 August 2028
Estimated completion	31 August 2030
Sites	2 locations across United States

Drugs / interventions tested

PRECEDE-PROCEED

Conditions studied

HPV — all drugs for HPV →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with HPV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cervical cancer is a disease that is preventable through vaccination against the virus that causes it, human papillomavirus (HPV), and through screening and treatment of cervical disease before it becomes cancet.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Implementation of Human Papillomavirus Self-Collection and Barriers to Follow-Up Among Unhoused Individuals in Texas: The EMPOWER Study.
Fallah PN, Bowman P, Tran C, Chen V, et al · · 2025 · PMID 40674748 · DOI 10.1097/aog.0000000000006003

Verify or expand the search:

Other recruiting trials for HPV

Currently open trials in the same condition.

NCT07493928 — HPV After chemoRadioTherapy · recruiting
NCT07065630 — Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer · Phase 2 · recruiting
NCT06796738 — Advancing Cervical Cancer Screening Through the Emergency Department - IIS · NA · active not recruiting
NCT07273383 — Self-sampling for HPV Screening · NA · active not recruiting
NCT07438080 — Concordance and Acceptability of Self-screening Compared to Screening Carried Out by a Health Professional for HPV, a Ri · NA · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06109870 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 4 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06109870.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing